Tag: daclatasvir

CATIE HepCinfo Update 6.17

New and Noteworthy Daclatasvir approved in Canada The Hep C drug daclatasvir (Daklinza) has been approved in Canada for people with genotype 1 or 2 virus. It has also been conditionally approved for people with genotype 3 virus pending the outcome of a late-stage clinical trial. Daclatasvir is taken with sofosbuvir (Sovaldi) for 12 weeks… Read more »

CATIE’s HepCInfo Update 6.12

New and Noteworthy Daclatasvir receives breakthrough therapy status from the FDA The U.S. Food and Drug Administration (FDA) has granted a breakthrough therapy designation for daclatasvir when used with the already approved medication sofosbuvir (Sovaldi) in people with advanced liver damage. When a medication is designated as a breakthrough therapy the FDA speeds up its… Read more »

CATIE’s HepCInfo Update 5.24

New and Noteworthy Harvoni cures 98% of Hep C and HIV co-infected participants with genotype 1 virus 98% of Hep C and HIV co-infected participants with genotype 1 virus who took Harvoni (ledipasvir + sofosbuvir) during a 12-week clinical trial were cured, reported researchers at the American Association for the Study of Liver Diseases (AASLD)… Read more »

CATIE’s HepCinfo Update 4.24

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:”Table Normal”; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:””; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:”Times New Roman”,”serif”;} New and Noteworthy New study estimates cases of hepatitis B and C, but experts warn figures may be too low A new federal government… Read more »